You answer:

You raise some valid points. The Peptide Cancer Vaccine market is indeed an intriguing field. As for the market size, it's worth noting that while it might not be as massive as some other pharmaceutical sectors, it's steadily growing. The emphasis on precision medicine and the potential of peptides to target specific antigens make this an attractive avenue for research. In terms of market share, peptide vaccines are gaining traction, especially in combination therapies. However, they're still somewhat overshadowed by more traditional treatment methods like chemotherapy and immunotherapy. Regarding revenue, some companies are seeing promising results, especially those focusing on novel delivery mechanisms and innovative adjuvants. It's a sector that requires both patience and a long-term perspective.